Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.
2.

West Nile Virus NS2B/NS3 protease as an antiviral target.

Chappell KJ, Stoermer MJ, Fairlie DP, Young PR.

Curr Med Chem. 2008;15(27):2771-84. Review.

PMID:
18991636
3.

Functional interplay among the flavivirus NS3 protease, helicase, and cofactors.

Li K, Phoo WW, Luo D.

Virol Sin. 2014 Apr;29(2):74-85. doi: 10.1007/s12250-014-3438-6. Epub 2014 Mar 26. Review.

PMID:
24691778
4.

The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development.

Luo D, Vasudevan SG, Lescar J.

Antiviral Res. 2015 Jun;118:148-58. doi: 10.1016/j.antiviral.2015.03.014. Epub 2015 Apr 2. Review.

PMID:
25842996
5.

The flavivirus protease as a target for drug discovery.

Brecher M, Zhang J, Li H.

Virol Sin. 2013 Dec;28(6):326-36. doi: 10.1007/s12250-013-3390-x. Epub 2013 Nov 14. Review.

6.

The nonstructural proteins of the hepatitis C virus: structure and functions.

Neddermann P, Tomei L, Steinkühler C, Gallinari P, Tramontano A, De Francesco R.

Biol Chem. 1997 Jun;378(6):469-76. Review.

PMID:
9224925
7.

Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target.

Raney KD, Sharma SD, Moustafa IM, Cameron CE.

J Biol Chem. 2010 Jul 23;285(30):22725-31. doi: 10.1074/jbc.R110.125294. Epub 2010 May 10. Review.

8.

Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets.

Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, Rice CM.

Antivir Ther. 1998;3(Suppl 3):71-81. Review.

PMID:
10726057
9.

Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.

Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG.

Antiviral Res. 2008 Nov;80(2):94-101. doi: 10.1016/j.antiviral.2008.07.001. Epub 2008 Jul 30. Review.

PMID:
18674567
10.

Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines.

De Francesco R, Neddermann P, Tomei L, Steinkühler C, Gallinari P, Folgori A.

Semin Liver Dis. 2000;20(1):69-83. Review.

PMID:
10895433
11.

Hepatitis C virus protease inhibitors: current progress and future challenges.

Steinkühler C, Koch U, Narjes F, Matassa VG.

Curr Med Chem. 2001 Jul;8(8):919-932. Review.

PMID:
11375758
12.

Hepatitis C virus NS3/4A protease.

Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA.

Antiviral Res. 1999 Feb;41(1):67-84. Review.

PMID:
10321580
13.

Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.

Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D.

J Viral Hepat. 2011 May;18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Epub 2011 Mar 23. Review.

PMID:
21470343
14.

Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.

Pillaiyar T, Namasivayam V, Manickam M.

Curr Med Chem. 2016;23(29):3404-3447. Review.

PMID:
27160539

Supplemental Content

Support Center